knowledge -WSS

knowledge

author：explore 2025-09-27 17:03:15 - browse：163

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： U.K. Biobank has 500,000 peoples' genome sequences available

WSS

Despite FDA concern, risk that CAR

Flagship Pioneering launches a new biotech in two countries

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Editas, Vertex strike deal on CRISPR

Rep. Raul Ruiz on the physician shortage and more

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

How one medical school became remarkably diverse

Takeda, Janssen join wearable maker to measure scratching

Malaria cases in Florida and Texas: Here’s what you need to know

BIO selects John Crowley as new CEO

Hollywood unions extend contract negotiations for actors

Why health records don't always know when patients are dead

How to save PrEP access — and even expand it

Bristol Myers buys into radiopharmaceuticals with RayzeBio

hotspot

ReNAgade cuts staff seven months after raising $300 million

Takeda, Janssen join wearable maker to measure scratching

Grail spinoff by Illumina should end disastrous merger attempt

Hospitals owned by private equity see complications spike 25%

CRISPR gene editing developments we’re watching in 2024

What to do when lifesaving products contribute to climate change

hotspot

knowledge

entertainment

leisure time